• Corcept Therapeutics reported long term survival data from its DAZALS Phase 2 trial of dazucorilant in ALS.
• Patients receiving 300 mg daily experienced an 87% reduction in risk of death at two years.
• The trial did not meet its primary functional endpoint, but the survival benefit attracted attention at the ENCALS 2025 meeting.

For investors tracking NasdaqCM:CORT, this new ALS data adds another layer to the story around Corcept Therapeutics beyond its core cortisol modulation work. The stock last closed at $51.05, with returns of 9.7% over the past week, 22.5% over the past month and 33.6% year to date, set against a 1 year decline of 28.5%. Over longer horizons, the stock shows gains of 113.5% over 3 years and 144.0% over 5 years.

The long term survival signal in DAZALS could influence how investors think about Corcept Therapeutics neurology pipeline if further data clarify the strength and consistency of the effect. ALS development is complex and high risk, so attention is likely to focus on how the company and regulators interpret survival versus functional outcomes, and what additional studies might be needed.

Stay updated on the most important news stories for Corcept Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Corcept Therapeutics.

The ALS survival data arrives at a time when Corcept’s fundamentals are in flux, which helps explain recent investor interest. The company reported a first quarter net loss of US$31.76 million compared with net income of US$20.55 million a year earlier, yet on the same day raised 2026 revenue guidance to US$950 million to US$1.05 billion. For investors, dazucorilant’s long term survival signal in ALS adds a new potential use case for Corcept’s cortisol modulation approach, alongside its recently approved Lifyorli in ovarian cancer and its hypercortisolism franchise.

How This Fits Into The Corcept Therapeutics Narrative

• The ALS survival data supports the existing narrative that expanding use of cortisol modulators across endocrinology, oncology and neurology could reduce dependence on a single product such as Korlym.
• The first quarter loss, together with the cost of running multiple late stage programs like DAZALS, challenges the idea that growth from new indications will translate smoothly into earnings without periods of higher spending.
• The ALS program and associated survival findings are not a central focus of the narrative, which concentrates more on hypercortisolism and ovarian cancer, so the potential impact of a neurology franchise may not be fully reflected.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Corcept Therapeutics to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ First quarter results swung from a US$20.55 million profit to a US$31.76 million loss, and analysts have highlighted weaker profit margins as a key risk.
• ⚠️ Analysts also flag legal and regulatory pressures on existing products, alongside pricing and margin pressure, which could limit how much new programs offset Korlym related risks.
• 🎁 Corcept is guiding to 2026 revenue of US$950 million to US$1.05 billion, supported by hypercortisolism prescriptions and early Lifyorli uptake.
• 🎁 The ALS survival data, together with progress in oncology and endocrinology, supports the view that the cortisol modulation pipeline could broaden the company’s opportunity set versus single drug focused biotech peers such as Incyte or Blueprint Medicines.

What To Watch Going Forward

From here, keep an eye on how regulators and clinicians respond to the DAZALS survival findings, including any moves toward a larger confirmatory trial or refined dosing based on Corcept’s gastrointestinal tolerability work. At the same time, watch whether the higher 2026 guidance holds up against future quarterly results as the company invests in multiple clinical programs and absorbs the costs that contributed to the recent loss. Insider trading plans and further disclosures around Korlym litigation and relacorilant’s regulatory path will also help investors judge how much of Corcept’s story is driven by diversification versus defending existing revenue streams.

To stay up to date on how the latest news impacts the investment narrative for Corcept Therapeutics, head to the community page for Corcept Therapeutics to follow the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.